170 related articles for article (PubMed ID: 37056328)
1. Development and validation of nomograms for predicting survival outcomes in patients with T1-2N1 breast cancer to identify those who could not benefit from postmastectomy radiotherapy.
Pu H; Luo Y; Zhang L; Li X; Li F; Chen J; Qian S; Tang Y; Zhao X; Hou L; Gao Y
Front Oncol; 2023; 13():1112687. PubMed ID: 37056328
[TBL] [Abstract][Full Text] [Related]
2. Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy.
Xu FF; Cao L; Xu C; Cai G; Wang SB; Qi WX; Chen JY
Front Oncol; 2022; 12():789198. PubMed ID: 35280719
[TBL] [Abstract][Full Text] [Related]
3. Nomogram-Based Risk Stratification to Identify Patients with T3N0M0 Breast Cancer with Survival Benefit from Postmastectomy Radiotherapy.
Meng X; Wang N; Qin P; Jia Q; Ju Z; Jiang Y
Ann Surg Oncol; 2024 Mar; 31(3):1634-1642. PubMed ID: 38087136
[TBL] [Abstract][Full Text] [Related]
4. The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype.
Wei J; Jiang Y; Shao Z
Breast; 2020 Jun; 51():40-49. PubMed ID: 32200207
[TBL] [Abstract][Full Text] [Related]
5. Postmastectomy radiotherapy in patients with T
Luo M; Jin Y; Xu C; Chen H; Zhang K; Chen Q; Jin C; Lu J; Wang J; Huang J; Deng H; Jin W; Zheng S; Chen Y; Zhou J
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9979-9990. PubMed ID: 37256383
[TBL] [Abstract][Full Text] [Related]
6. Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes.
Tang Y; Zhang YJ; Zhang N; Shi M; Wen G; Cheng J; Wang HM; Liu M; Wang XH; Guo QS; Wu HF; Ma CY; Jin J; Liu YP; Song YW; Fang H; Ren H; Wang SL; Li YX
Cancer; 2020 Aug; 126 Suppl 16():3857-3866. PubMed ID: 32710662
[TBL] [Abstract][Full Text] [Related]
7. Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes.
Zhang N; Zhang J; Zhang H; Liu Y; Zhao W; Wang L; Chen B; Moran MS; Haffty BG; Yang Q
Oncologist; 2019 Dec; 24(12):e1286-e1293. PubMed ID: 31315963
[TBL] [Abstract][Full Text] [Related]
8. The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer.
Zhang L; Tang R; Deng JP; Zhang WW; Lin HX; Wu SG; He ZY
BMC Cancer; 2020 Nov; 20(1):1146. PubMed ID: 33238939
[TBL] [Abstract][Full Text] [Related]
9. Postmastectomy radiation therapy can improve survival for breast cancer patients with 1-3 positive axillary lymph nodes: a retrospective cohort study using the SEER database.
Yang J; Zhang X; Ye Y; Lin Y; Yang Q; Cai H
Transl Cancer Res; 2021 May; 10(5):1984-2001. PubMed ID: 35116521
[TBL] [Abstract][Full Text] [Related]
10. The prognostic differences and the effect of postmastectomy radiotherapy between post-chemotherapy ypT1-2ypN1 and de novo pT1-2N1 breast cancer.
Yang T; Zhong X; Wang J; Xiang Z; Zeng Y; Yu S; Dai Z; Xu N; Luo T; Liu L
Cancer Med; 2023 Apr; 12(7):8112-8121. PubMed ID: 36734308
[TBL] [Abstract][Full Text] [Related]
11. The Value of the 8th Edition of American Joint Committee on Cancer Pathological Prognostic Staging on the Selection of Postmastectomy Radiotherapy for T1-2N1 Breast Cancer.
Wang J; Zhong XR; Luo T; Xiang ZZ; Zeng YY; Yang T; Zheng H; Liu L
J Oncol; 2022; 2022():7550323. PubMed ID: 36330354
[TBL] [Abstract][Full Text] [Related]
12. Nomogram Predicting Locoregional Recurrence to Assist Decision-Making of Postmastectomy Radiation Therapy in Patients With T1-2N1 Breast Cancer.
Luo C; Zhong X; Deng L; Xie Y; Hu K; Zheng H
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):905-912. PubMed ID: 30419307
[TBL] [Abstract][Full Text] [Related]
13. [Effect of postmastectomy radiotherapy on survival outcomes of patients with metaplastic breast cancer].
Cai W; Zhuang Y; Chen J; Wang H
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Nov; 41(11):1733-1740. PubMed ID: 34916202
[TBL] [Abstract][Full Text] [Related]
14. Effect of postmastectomy radiotherapy on pT1-2N1 breast cancer patients with different molecular subtypes: A real-world study based on the inverse probability of treatment weighting method.
Ye S; Hu W
Medicine (Baltimore); 2022 Sep; 101(37):e30610. PubMed ID: 36123865
[TBL] [Abstract][Full Text] [Related]
15. The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database.
Lin J; Luo S; Zhang J; Song C
BMC Geriatr; 2023 Oct; 23(1):625. PubMed ID: 37803254
[TBL] [Abstract][Full Text] [Related]
16. A Nomogram and Risk Classification System Predicting the Prognosis of Patients with De Novo Metastatic Breast Cancer Undergoing Immediate Breast Reconstruction: A Surveillance, Epidemiology, and End Results Population-Based Study.
Zhao J; Bian S; Di X; Xiao C
Curr Oncol; 2023 Dec; 31(1):115-131. PubMed ID: 38248093
[TBL] [Abstract][Full Text] [Related]
17. [Risk-adapted postmastectomy radiotherapy based on local-regional recurrence for T1-2N1M0 breast Cancer].
Li M; Wang SL; Fang H; Tang Y; Chen B; Qi SN; Song YW; Liu YP; Lu NN; Li N; Tang Y; Ren H; Jin J; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):841-849. PubMed ID: 29151291
[No Abstract] [Full Text] [Related]
18. Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study.
Yin F; Wang S; Hou C; Zhang Y; Yang Z; Wang X
Front Public Health; 2022; 10():969030. PubMed ID: 36203704
[TBL] [Abstract][Full Text] [Related]
19. The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data.
Dai Y; Ma S; Lan A; Wang Y; Wang Y; Jin Y; Ding N; Jiang L; Tang Z; Yin X; Peng Y; Liu S
Discov Oncol; 2023 Jan; 14(1):2. PubMed ID: 36609653
[TBL] [Abstract][Full Text] [Related]
20. Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis?
Kong M; Hong SE
Cancer Res Treat; 2013 Jun; 45(2):103-11. PubMed ID: 23864843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
